Abstract
Prevalence of obesity and bronchial asthma is increasing in industrialized countries. Several studies have suggested a relationship between these disorders. Evidence comes from studies with animal models as well as epidemiologic observations. Moreover, pulmonary function parameters, genetic and hormonal factors support the hypothesis that obesity and asthma are linked. Given the enormous economic impact effective and efficient treatment strategies for both diseases are important. The present review will describe patents and recent developments in drugs directed against obesity and asthma. Potential therapeutic targets include the ORL-1 receptor, the LPA receptor, the VEGF receptor, cannaboid receptor, T cells, and protein kinases.
Keywords: Asthma, cannaboid receptor, LPA receptor, obesity, ORL-1 receptor, protein kinase, T cell, VEGF receptor
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery
Title: Obesity and Asthma
Volume: 3 Issue: 3
Author(s): Hans-Peter Hauber and Michael Wegmann
Affiliation:
Keywords: Asthma, cannaboid receptor, LPA receptor, obesity, ORL-1 receptor, protein kinase, T cell, VEGF receptor
Abstract: Prevalence of obesity and bronchial asthma is increasing in industrialized countries. Several studies have suggested a relationship between these disorders. Evidence comes from studies with animal models as well as epidemiologic observations. Moreover, pulmonary function parameters, genetic and hormonal factors support the hypothesis that obesity and asthma are linked. Given the enormous economic impact effective and efficient treatment strategies for both diseases are important. The present review will describe patents and recent developments in drugs directed against obesity and asthma. Potential therapeutic targets include the ORL-1 receptor, the LPA receptor, the VEGF receptor, cannaboid receptor, T cells, and protein kinases.
Export Options
About this article
Cite this article as:
Hauber Hans-Peter and Wegmann Michael, Obesity and Asthma, Recent Patents on Endocrine, Metabolic & Immune Drug Discovery 2009; 3 (3) . https://dx.doi.org/10.2174/187221409789104773
DOI https://dx.doi.org/10.2174/187221409789104773 |
Print ISSN 1872-2148 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3334 |
Related Articles
-
Protein and Peptide Biopharmaceuticals: An Overview
Protein & Peptide Letters The Gut-Brain Axis, Including the Microbiome, Leaky Gut and Bacterial Translocation: Mechanisms and Pathophysiological Role in Alzheimer’s Disease
Current Pharmaceutical Design Occupational Exposure and Respiratory Tract Infections –At Risk Workers in the International Context
Current Respiratory Medicine Reviews Preparation of Quercetin Loaded Microparticles and their Antitumor Activity against Human Lung Cancer Cells (A549) in vitro
Current Pharmaceutical Biotechnology IL-23/Th17 Axis: A Potential Therapeutic Target of Psoriasis
Current Drug Research Reviews Anti-Diabetic Drugs GLP-1 Agonists and DPP-4 Inhibitors may Represent Potential Therapeutic Approaches for COVID-19
Endocrine, Metabolic & Immune Disorders - Drug Targets Therapeutic Challenges in Neuroendocrine Tumors
Anti-Cancer Agents in Medicinal Chemistry Breath Analysis: The Approach Towards Clinical Applications
Mini-Reviews in Medicinal Chemistry Synthesis of pyridyl benzimidazoles encompassing 4-thiazolidinone derivatives as potential antimicrobial agents
Letters in Drug Design & Discovery Pivotal Role of Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 in Inflammatory Pulmonary Diseases
Current Protein & Peptide Science Lactoferrin as a Natural Immune Modulator
Current Pharmaceutical Design Computational Studies Applied to Anti-inflammatory Drug Discovery: A Review
Current Organic Chemistry Dietary Approaches and Supplements in the Prevention of Cognitive Decline and Alzheimer's Disease
Current Pharmaceutical Design Paracetamol-Induced Fixed Drug Eruption at an Unusual Site
Recent Patents on Inflammation & Allergy Drug Discovery Analgesia in PACU: Nonsteroidal Anti-Inflammatory Drugs
Current Drug Targets Evaluation of Novel 7-(hetero)aryl-substituted Pyrazolo[1, 5-a]pyrimidines as Phosphodiesterase-4 Inhibitors
Letters in Drug Design & Discovery IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System
Current Drug Targets Prediction of Comparative Inhibition Efficiency for a Novel Natural Ligand, Galangin Against Human Brain Acetylcholinesterase, Butyrylcholinesterase and 5-Lipoxygenase: A Neuroinformatics Study
CNS & Neurological Disorders - Drug Targets T Cell Targeted Strategies for Improved Efficacy and Safety of Specific Immunotherapy for Allergic Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Natural Anti-inflammatory Compounds as Drug Candidates in Alzheimer’s Disease
Current Medicinal Chemistry